Rani's Oral Obesity Drug RT-114 Beats Injectable on Bioavailability in Phase 1a
RANI sits 75% above its 52-week low of $0.387.
Summary
Rani's oral GLP-1/GLP-2 dual agonist RT-114 achieved >150% bioavailability versus the same subcutaneous dose in a Phase 1a study of 30 healthy volunteers. No serious adverse events were reported, and side effects were mild and transient, consistent with the class. The elimination half-life was similar between oral and injectable arms, supporting once-weekly oral dosing potential. This is the first clinical validation of the RaniPill platform in obesity, a massive market dominated by injectables. The company is expanding the study with an additional cohort to refine dosing before a Phase 1b trial in obese patients, expected to start later this year with data in 2027. The stock, trading near $0.68 with a ~$88M market cap, could see significant re-rating if the platform proves viable in larger trials.
At the time of this announcement, RANI was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88.5M. The 52-week trading range was $0.39 to $3.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.